https://prabadinews.com/
  • October 9, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

ENDO 2025: GLP-1 Receptor Agonists as Multisystem Therapies in Type 2 Diabetes Management

ENDO 2025: GLP-1 Receptor Agonists as Multisystem Therapies in Type 2 Diabetes Management

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the expanding role of GLP-1 receptor agonists in holistic type 2 diabetes care, highlighting their cardio-renal-hepatic benefits, clinical access challenges, emerging investigational therapies, and practical strategies for individualized, guideline-based prescribing.

administrator

Related Articles